The Phia Group Blog

By: Naga Vivekanandan, Esq. Medicare has spent years watching GLP-1 drugs move from a promising diabetes therapy to one of the most consequential drivers of prescription drug spending. That shift has been fueled by strong clinical results, expanding indications, and…

By: David Ostrowsky For some Americans, there is a natural tendency to conflate healthcare with health insurance. Perhaps on the surface, they seem one and the same, but in reality, of course, they are entirely different entities: the former involves…

By: Jen McCormick and David Ostrowsky Prior. Authorization. Lumped together, the two words have long been the bane of patients’ experience in navigating an often-byzantine healthcare system. Whether you’re a patient with diabetes waiting ever-so patiently for insulin or one…

By: Kendall Jackson For many, the start of a new year offers a breath of fresh air, particularly for those who were working tirelessly to complete important end-of-year administrative tasks. From making changes to benefits and implementing plan document updates…

By: David Ostrowsky Among the many issues that Americans—both patients and practitioners—have with their country’s healthcare system are that a.) the administrative hassles for insurance matters can be burdensome and b.) the patient-doctor relationship is increasingly void of good old…

By: David Ostrowsky Many Americans have long viewed melatonin as a harmless supplement that’s readily accessible on the shelf at the local grocers or CVS. Certainly, millions consider melatonin to be an effective sleep aid with minimal side effects and…